Prevention of chronic renal allograft rejection by soluble CD83.
Lan Z, Lian D, Liu W, Arp J, Charlton B, Ge W, Brand S, Healey D, DeBenedette M, Nicolette C, Garcia B, Wang H. Transplantation. 2010 Dec 27;90(12):1278-85.
Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2,3-dioxygenase.
Lan Z, Ge W, Arp J, Jiang J, Liu W, Gordon D, Healey D, DeBenedette M, Nicolette C, Garcia B, Wang H Transplantation. 2010 Dec 27;90(12):1286-93.
Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection.
Ge W, Arp J, Lian D, Liu W, Baroja ML, Jiang J, Ramcharran S, Eldeen FZ, Zinser E, Steinkasserer A, Chou P, Brand S, Nicolette C, Garcia B, Wang H. Transplantation. 2010 Dec 15;90 (11):1145-56.
Structural identification of recombinant human CD83 mutant variant as a potent therapeutic protein.
Zhang L, Narayanan N, Brand SR, Nicolette CA, Baroja M, Arp J, Wang H, Moo-Young M, Chou CP. Protein Expr Purif. 2010 Oct;73(2):140-6. Epub 2010 Jun 8.
Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection
Routy JP, Nicolette C. Immunotherapy. 2010 Jul; 2(4):467-76.
A Short Pulse of IL-4 Delivered by DCs Electroporated With Modified mRNA Can Both Prevent and Treat Autoimmune Diabetes in NOD Mice.
RJ Creusot, P Chang, DG Healey, IY Tcherepanova, CA Nicolette and CG Fathman. Molecular Therapy (2010); 18 12, 2112–2120 Read more
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
Routy J, Boulassel M, Yassine-Diab Y, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Finke L and Sekaly R. Clin. Immunol., 134, 140-147 (2010).
Development of a cellular immunotherapy for ART naïve patients for the purpose of delaying or preventing initiation of ART therapy.
I.Y. Tcherepanova, D.M. Calderhead, M.A. DeBenedette, R.Jain, J.P. Routy, C.A. Nicolette HIV DART (2010), Los Cabos, Mexico. Poster
A Phase 1/2 Study of AGS-003, a personalized immunotherapeutic evaluated in newly diagnosed metastatic renal cell carcinoma subjects
T. Logan, A. Amin, V. Cohen, M. K. K. Wong, V. A. Master, T. Monesmith, D. Healey, R. Jain, D. Plessinger, C. A. Nicolette. ASCO 2010 Genitourinary Cancers Symposium, San Francisco, CA (2010). Abstract # 379.
Mature Dendritic Cells Electroporated with CD40L RNA Produce IL-12 a Critical Component of Dendritic Cell Based Immune-Therapy Necessary for the Induction of Multi-Functional Effector/Memory CD8+/CD28+ CTL.
M. DeBenedette, D. Calderhead, I. Tcherepanova, C. Nicolette and D. Healey. Keystone Symposia – Immunological Mechanisms of Vaccination (S1) (2010) Seattle, WA USA
Cancer Immunotherapy: A long awaited reality.
October 21, 2010 New York Academy of Medicine New York City. AN EXCLUSIVE CONFERENCE EVENT & TELEVISED SERIES. Fred Miesowicz and Charles Nicolette presentation.
Webinar with leading researchers in renal cell carcinoma (RCC) to discuss novel therapies, recently approved or in development, as well as the promise of personalized immunotherapy in the treatment of RCC.
November 1, 2010 (Webinar link)
The Argos Approach to Personalized Dendritic Cell Immunotherapies.
F. Miesowicz. ISPE Fall Annual Gala for the local CASA chapter in Cary, NC USA (2010)
Assessing & Implementing Automation session/panel discussion.
F. Miesowicz. Cell Therapy Industry Summit hosted by Invitrogen Carlsbad, CA Nov 2010
Process Development and Clinical Manufacturing for Autologous Dendritic Cell Immunotherapies
T. Monesmith. BioProcess International Conference and Convention Providence RI USA (Sep 2010)
Encouraging progression free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) participating in a phase II study testing the safety and activity of a dendritic cell-based immunotherapeutic (AGS-003) in combination with sunitinib
RA Figlin, A Amin, AZ Dudek, T Logan, RS Lance, JM Holzbeierlein, WL Williams, RG Jain, T. Monesmith, I. Tcherepanova, F Miesowicz, CA Nicolette, AGS-003-006 Study Group. Ninth International Kidney Cancer Symposium Chicago, IL USA (2010) Poster
An autologous AI approach to treating HIV infection.
CA Nicolette, IY Tcherepanova, D Healey, D Calderhead, M DeBenedette, R Jain, WL Williams, T Monesmith, F Miesowicz, JP Routy, J Jacobson, AGS-004-001 Study Group. Active Immunotherapeutics forum, Barcelona, Spain (2010)
A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib
A Amin, AZ Dudek, T Logan, RS Lance, JM Holzbeierlein, WL Williams, RG Jain, IY Tcherepanova, CA Nicolette, TT Monesmith, RA Figlin, AGS-003-006 Study Group. ASCO 2010 Annual Meeting (2010) Chicago, IL USA, Abstract # 4588
A novel method to improve antigen presentation and immunopotency of RNA-loaded monocyte-derived dendritic cells.
I. Tcherepanova, A. Raney, B. Martin, M. Norris, T. Monesmith, M. DeBenedette, F. Miesowicz, and C.A. Nicolette. 22 nd EORTC-NCI-AACR (2010) Berlin.
Evaluation of the Agilent Bioanalyzer 2100 for quality determination of IVT RNA.
JG Slagter-Jäger, C Nicolette and I Tcherepanova. 15th Annual Meeting of RNA society, Seattle WA, USA (2010).
Immunologic activity of a fully autologous dendritic cell immunotherapy for the treatment of HIV-1 infected subjects.
D Healey, B Yassine-Diab, Z Coutsinos, C Landry, D Gagnon, C Hebert-Benoit, R Boulassel, JP Routy, S Vezina, C Tremblay, M Loutfy, F Smaill, J Gill, JG Baril, R Jain, I Tcherepanova, and RP Sekaly, CA Nicolette. XVIII International AIDS Conference, Vienna, Austria (2010).
HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to pre-ART viral load) and delay in the time to viral rebound during a 12 week structured treatment interruption (STI).
J.P. Routy, J. Angel, S. Vezina, C. Tremblay, M. Loutfy, J. Gill, J.G. Baril, F. Smaill, R. Jain, I. Y. Tcherepanova, R. Boulassel, T. Monesmith, R. P. Sekaly, C. A. Nicolette, AGS 004-001 Study Group. XVIII International AIDS Conference, Vienna, Austria (2010). Poster # MOPDB101.
AGS-004, an autologous dendritic cell therapy impacts on the evolution of residual HIV virus along with a substantial increase in time to viral rebound, during an STI in the CTN 239 clinical study
Tcherepanova I, Boulassel MR, Carreno A, Carpenter H, Loutfy MR, Vezina S, Tremblay C, Angel, J, Gill J, Baril, J, Smaill F, Jain R, Healey D, Chew T , Nicolette C. and Routy JP. 19th Annual Canadian Conference on HIV/AIDS Research, Saskatoon, Canada (2010).
Study of rebound virus genetic diversity in subjects treated with autologous DC based (AGS-004) immunotherapy after ART interruption.
I.Y. Tcherepanova, A.D. Carreño, J.H. Carpenter, J. Harris, J.P. Routy, R. Jain, D. Healey, T. Chew and C.A. Nicolette. Keystone Symposium: HIV Vaccines. Banff, Canada (2010)
Challenges of Manufacturing Autologous Cell Therapies.
T. Monesmith NC State ISPE student chapter Raleigh NC, USA (2010)
Safety and Viral load changes in HIV-1 infected subjects treated with autologous dendritic immune therapy following ART discontinuation.
Routy J, Boulassel M, Loutfy M, Vezina S, Tremblay C, Angel J, Gill J, Baril J, Smaill F, Jain R, Healey D, Tcherepanova I, Nicolette C and Sekaly R. Oral Presentation